Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations: Difference between revisions
| [unchecked revision] | [unchecked revision] |
inserting Table 1 from the original paper |
m Jennelleh moved page TestPCDtable to Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations without leaving a redirect |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
'''Table 1 - | '''Table 1 - Clinically significant cytogenomic alterations in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. See Table 2 for references and Level 3 evidence. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics. | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Evidence Level''' | |'''Evidence Level''' | ||
| Line 8: | Line 8: | ||
| rowspan="11" |'''Level 1''' | | rowspan="11" |'''Level 1''' | ||
well established evidence in NCCN guideline, WHO criteria, FDA-approved, COG recommendation, or based on large body of publications. | well established evidence in NCCN guideline, | ||
WHO criteria, FDA-approved, COG | |||
recommendation, or based on large body of publications. | |||
|Hyperdiploidy (+3, +5, +7, +9, +11, +15, +21) | |Hyperdiploidy (+3, +5, +7, +9, +11, +15, +21) | ||
|Good prognosis | |Good prognosis | ||
| Line 15: | Line 19: | ||
|t(4;14) | |t(4;14) | ||
|Poor prognosis, predicts bortezomib response | |Poor prognosis, predicts bortezomib response | ||
|''IGH'' | |''[[IGH]]'' | ||
|- | |- | ||
|t(6;14) | |t(6;14) | ||
|Good prognosis | |Good prognosis | ||
|''IGH'' | |''[[IGH]]'' | ||
|- | |- | ||
|t(14;16) | |t(14;16) | ||
|Poor prognosis | |Poor prognosis | ||
|''IGH'' | |''[[IGH]]'' | ||
|- | |- | ||
|t(11;14) | |t(11;14) | ||
|Good prognosis | |Good prognosis | ||
|''IGH'' | |''[[IGH]]'' | ||
|- | |- | ||
|t(14;20) | |t(14;20) | ||
| Line 90: | Line 94: | ||
|8q24.2+ | |8q24.2+ | ||
|Recurrent | |Recurrent | ||
|''MYC'' | |''[[MYC]]'' | ||
|- | |- | ||
|9p+ | |9p+ | ||
| Line 98: | Line 102: | ||
|del(10q23.31) | |del(10q23.31) | ||
|Recurrent | |Recurrent | ||
|''PTEN'' | |''[[PTEN]]'' | ||
|- | |- | ||
|11q+ | |11q+ | ||
| Line 110: | Line 114: | ||
|del(13q32.2) | |del(13q32.2) | ||
|Recurrent | |Recurrent | ||
|''TGDS'' | |''[[TGDS]]'' | ||
|- | |- | ||
|del(14q) | |del(14q) | ||
| Line 154: | Line 158: | ||
|22q21+ | |22q21+ | ||
|Associated with relapse | |Associated with relapse | ||
|''PRAME'' | |''[[PRAME]]'' | ||
|- | |- | ||
|del(X), X+, X CN-LOH | |del(X), X+, X CN-LOH | ||
| Line 164: | Line 168: | ||
| | | | ||
|} | |} | ||
'''Table | |||
'''Table 2 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics. | |||
{| class="wikitable" | {| class="wikitable" | ||
|'''Chromosome''' | |'''Chromosome''' | ||
| Line 690: | Line 696: | ||
| 17p13 | | 17p13 | ||
|Loss | |Loss | ||
|''[[ATP1B2]], | |''[[ATP1B2]], [[TP53]], [[WRAP5]], [[EFNB3]]'' | ||
| Predictive & prognostic | | Predictive & prognostic | ||
|1 | |1 | ||